Idenix Pharmaceuticals' CEO Provides Update On IDX184 Clinical Development Program Conference (Transcript)

Idenix Pharmaceuticals, Inc. (IDIX)

Update on IDX184 Clinical Development Program Conference Call

August 16, 2012 08:30 am ET

Executives

Daniella Beckman - SVP & CFO

Ron Renaud - President & CEO

Doug Mayers - EVP & CMO

David Standring - EVP & CSO

Analysts

Geoff Meacham - JPMorgan

Katherine Xu - William Blair

Yaron Werber - Citi

Howard Liang - Leerink Swann

Matt Roden - UBS

Daniel Brims - Brean Murray

Liisa Bayko - JMP

David Friedman - Morgan Stanley

Ying Huang - Barclays

Jim Birchenough - BMO Capital

Mark Schoenebaum - ISI Group

Yaron Werber - Citi

Presentation

Operator

Compare to:
Previous Statements by IDIX
» Idenix Pharmaceuticals' CEO Presents Restructuring of Development and Commercialization Collaboration With Novartis Pharma AG Call (Transcript)
» Idenix Pharmaceuticals' CEO Presents at Deutsche Bank 37th Annual Healthcare Conference (Transcript)
» Idenix Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript

Good day ladies and gentlemen and welcome to the Idenix provides update on IDX184 clinical development conference call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will be given at that time. (Operator Instructions) As a reminder, today’s call is being recorded.

I would now like to turn the conference over to Ms. Daniella Beckman. Ma'am, you may begin.

Daniella Beckman

Thank you. Good morning and welcome to Idenix Pharmaceuticals conference call to discuss the clinical development and status of our lead drug candidate, IDX184. My name is Daniella Beckman and I am the Chief Financial Officer at Idenix.

On this morning’s call is Ron Renaud, President and Chief Executive Officer; Doug Mayers, Chief Medical Officer, who has dialed in remotely and David Standring, Chief Scientific Officer.

Before we begin, I'll review our Safe Harbor statement. Today’s discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of factors that could cause actual results to differ materially.

1 2 3 Next › Last »